GEN1d
C3i Center Receives EMA Approval to Manufacture Cell Therapy Products for Europe
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
C3i Center, a Canadian company, receives approval from the EMA to manufacture cell therapy products for the European market
The company received a certificate of Good Manufacturing Practice (GMP) compliance following an inspection of their Montreal facility by the European Medicines AgencyMONTRÉAL, Feb. 19, 2025 (GLOBE ...
Canadian Manufacturing1d
C3i to manufacture cell therapy products for European market
MONTRÉAL — C3i Center obtains regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. C3i, therefore, obtains a certificate of GMP ...